Loading...
•
Dec 31, 2020
TransMedics Q4 2020 Earnings Report
TransMedics reported fourth quarter financial results exceeding expectations, driven by the recovery of U.S. OCS Lung procedure volumes and progress with OCS DCD Heart and OCS Liver CAP clinical programs.
Key Takeaways
TransMedics Group, Inc. reported a net revenue of $7.6 million for the fourth quarter of 2020, representing a 26% increase compared to the fourth quarter of 2019. The increase was primarily due to the recovery of U.S. sales led by OCS Lung activities. The net loss for the quarter was $6.3 million, compared to $9.2 million in the same period in 2019.
Net revenue reached $7.6 million, a 26% increase compared to Q4 2019.
Gross margin improved to 63% from 62% in Q4 2019.
Operating expenses decreased to $10.7 million from $12.4 million in Q4 2019.
Net loss decreased to $6.3 million from $9.2 million in Q4 2019.
Forward Guidance
The company is focused on leveraging the progress made with the National OCS Program in 2020 and advancing FDA initiatives to accelerate growth through 2021 and beyond.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...